U.K. cash incentives for generics-switching draw fire; Sanofi settles more Eloxatin patent suits;

@FiercePharma: Final Four coach did time as pharma sales rep. Article | Follow @FiercePharma

> The U.K.'s National Health Service risks losing millions of pounds after a European legal opinion that calls for a ban on the growing practice of paying doctors to persuade them to prescribe cheaper generic medicines. Report

> Sanofi-Aventis has settled patent infringement suits with three more generic drugmakers over its cancer drug Eloxatin, putting off their copycat versions till August 2012. Report

> For the second time in six months, Merck is going to court to defend its patents for Cancidas, an intravenous drug that treats life-threatening fungal infections, against generic competitors. Report

> The FDA approved a reformulated version of the powerful painkiller OxyContin that is designed to make it harder to tamper with the product. Release | Report

> Many children starting treatment with atypical antipsychotics don't get the recommended glucose and lipid screening, an Archives of Pediatric and Adolescent Medicine study found. Report 

> Dishman Pharmaceuticals & Chemicals, an Indian drugmaker, plans to raise 750 million rupees ($17 million) next month selling non-convertible bonds to build new plants, Managing Director J.R. Vyas said. Report

> The Drug Controller General of India has asked Dr Reddy's Laboratories to provide details about its relationships with doctors in the wake of revised conflicts-of-interest guidelines from the Medical Council of India. Report

> A growing number of overdoses of legal opioids, sedatives and tranquilizers led to a 65 percent increase in hospitalizations over seven years. Report

Biotech News

 @FierceBiotech: Florida city carves out 1-square-mile biotech hub. Article | Follow @FierceBiotech

 @JohnCFierce: Biotech Deal Activity Takes a Breather. It's been too quiet on that front. I hate dull. Report | Follow @JohnCFierce

> Tengion braves a chilly market with $41 million IPO. Article

> Is ailing Antisoma a prime new takeover target? Item

> GSK, Crucell join R&D forces on new malaria vaccine. Story

> A blockbuster FDA deadline looms and Dendreon shares turn red-hot. Report

Manufacturing News

> MIT's Hockfield: "Time to get busy reinventing manufacturing." Report

> Chinese regulator faces bribery charge in vaccine scandal. Story

> Perrigo loses $400,000 in drug shipment theft. Item

> Report: Add REMS to Sentinel System. Story

Biotech Research News

> Explosion of cancer drug trials spurs a new approach. Story

> Researchers find "weak link" in Alzheimer's therapies. Report

> A research team in the U.K. is proposing that a new group of synthetic molecules could play a lead role fighting cancer, inflammation and other diseases. Story

> Lab breakthrough opens door to new generation of antibiotics. Item

> Genetics research pointing to new longevity drug pathways. Article

And Finally... Demand for prescription assistance in the U.S. has increased sharply following the 2008 economic crisis. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.